4C Medical Technologies (Brooklyn Park, MN) is focused on minimally invasive therapies for structural heart disease, specifically mitral valve regurgitation.
ATRO Medical (Nijmegen, Netherlands) – TRAMMPOLIN (Total ReplAcement of Meniscus with Minimally invasive POLymer ImplaNt) is a synthetic, non‐resorbable total meniscus substitute.
Carmell Therapeutics (Pittsburgh, PA) has created a unique and highly innovative patented technology based on biologically-active materials manufactured from human blood plasma. Our proprietary process binds and cross-links lyophilized plasma into solid and semi-solid plasma-based materials. These Plasma-based Bioactive Materials (PBMs) contain highly concentrated natural regenerative factors that promote healing in various clinical settings, reduce infections, and, as a result, lower healthcare costs.
Conavi Medical (Toronto, Ontario, Canada) is a commercial-stage medical device company that develops image guidance technologies for use in minimally invasive procedures, with an initial focus in cardiology.
CorFlow Therapeutics AG (Baar, Switzerland) is developing the first combined diagnostic and therapeutic medical device for improving microvascular obstructions after a heart attack.
Hemovent GmbH (Aachen, Germany) is an emerging medical device company that has developed disruptive technology: the world’s smallest and first self-contained fully portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure.
ID-NEST Medical (Alsace, France) is developing the first fully compliant branched endograft system. Our innovative ‘click-connect’ technology brings a long-term patency solution to some vascular indications that are ill-treated at the moment. Our Venous range is targeting Compressed Illiac Veins (May-Thurner Syndrom) that affects millions in all countries. The Arterial version will dramatically improve the treatment of Aortic Arch Aneurysms, currently a delicate operation to manage.
MangoGen Pharma (Quebec, Canada) is developing gene-delivering cardiac stents and wound healing creams.
Newronika SRL (Milan, Italy) restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life.
Promaxo (Rockville, MD) is a medical device company developing and commercializing an office-based and cost effective MRI with cellular level spatial resolution, real time biopsy and treatment tools, and automated software for tissue characterization. The Company’s current focus is on addressing the needs of the prostate cancer market.
Quanta Dialysis Technologies Ltd. (Alcester, United Kingdom) is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines.
Raydiant Oximetry (Mountain View, CA) has developed a novel fetal monitor that more accurately measures fetal distress. This technology will improve childbirth related outcomes for expecting mothers and their babies.
RSP Systems A/S (Odense, Denmark) is dedicated to improving the health and quality of life of people worldwide through its unique and patented solution for non-invasive diagnostics. The first targeted application is a product line of noninvasive glucose monitors, which will provide diabetic patients with a convenient, pain free alternative to the current invasive solutions.
Vivior’s (Zurich, Switzerland) sensor technology provides objective behavioral data to support medical experts in offering personalized vision solutions to their patients.